There are 3484 resources available
424P - Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
Presenter: Xichun Hu
Session: Poster session 03
425P - Real world quality of life (QoL) in breast cancer (BC) patients treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i)
Presenter: Blanca Tavara
Session: Poster session 03
427P - Pyrotinib plus trastuzumab versus pertuzumab plus trastuzumab in patients with HER2-positive metastatic breast cancer: A multicenter, retrospective study
Presenter: biyun Wang
Session: Poster session 03
428P - Palbociclib dose patterns in Swedish patients with metastatic breast cancer: 5-year update from the SIRI study
Presenter: Antonis Valachis
Session: Poster session 03
429P - The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study
Presenter: Hasan Yildirim
Session: Poster session 03
430P - Real-world patient characteristics and treatment patterns in HR+/HER2+ metastatic breast cancer patients in 5 European countries
Presenter: Carmen Criscitiello
Session: Poster session 03
431P - Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2- metastatic breast cancer (MBC) patients (pts)
Presenter: Eleonora Nicolo
Session: Poster session 03
432P - Ki67 and progesterone receptor status could be predict sensitivity to cyclin-dependent kinase inhibitor
Presenter: Lucia Navarro Berlanga
Session: Poster session 03
433P - Effectiveness and safety of vinorelbine + inetetamab + pyrotinib in ≥second-line treatment of HER2-positive metastatic breast cancer
Presenter: Wu Fan
Session: Poster session 03